Engineered nanovesicle platform simultaneously triggers YAP-dependent ferroptosis and reprograms T-cell immunity through miR-150-3p codelivery in melanoma microenvironment
Quick Facts
- Publication title: Engineered nanovesicle platform simultaneously triggers YAP-dependent ferroptosis and reprograms T-cell immunity through miR-150-3p codelivery in melanoma microenvironment
- Journal: Theranostics
- Year: 2025
- DOI: 10.7150/thno.115860
- PMID/PMCID: 40860143; PMC12374587
Research overview
To address these limitations, we developed an engineered EV strategy integrating efficient miRNA packaging with tumor-targeting surface modifications to enhance therapeutic outcomes in melanoma. Ferroptosis induction was evaluated through lipid peroxidation analysis, mitochondrial membrane potential assays, and transmission electron microscopy (TEM).
Key findings
Rationale: Melanoma remains a highly aggressive malignancy with limited effective therapies and frequent resistance to immune checkpoint blockade (ICB).
Extracellular vesicles (EVs) represent a promising platform for RNA-based therapeutics, but their clinical translation is impeded by inefficient cargo loading and insufficient tumor-specific targeting.
To address these limitations, we developed an engineered EV strategy integrating efficient miRNA packaging with tumor-targeting surface modifications to enhance therapeutic outcomes in melanoma.
Methods: Engineered EVs (iEV-150) were generated by co-expressing miR-150-3p and Annexin A2 (ANXA2) in HEK293T cells, followed by surface modification with tumor-targeting iRGD peptides.
Echo Biotech Role
Echo Biotech contributed EV isolation and purification, targeting-peptide/surface modification; the study also used or cited Exosupur®, ExoBrooch™.
Related platforms: Exoomics®, Echosome®, Research Reagents & Tools
Related services and capabilities: Biofluid EV Isolation & Purification, Targeting Peptide / Surface Modification, Research Reagent / Product Supply
Related products or reagents: Exosupur® EV Isolation/Purification Kit, ExoBrooch™ Targeting Peptide/Lipid Anchor Kit
References
Original publication: Engineered nanovesicle platform simultaneously triggers YAP-dependent ferroptosis and reprograms T-cell immunity through miR-150-3p codelivery in melanoma microenvironment Theranostics. 2025. DOI: 10.7150/thno.115860. PMID/PMCID: 40860143; PMC12374587.